ReviewActa pharmacologica Sinica2026
Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial antiviral signalling protein (MAVS), also known as interferon-β (IFN-β) promoter stimulator 1 (IPS-1), virus-induced signalling adaptor (VISA), and CARD adaptor inducing IFN-β (CARDIF), has emerged as a regulatory node linking mitochondrial stress, innate immune signalling, and cardiovascular disease (CVD) pathogenesis. In the cardiovascular system, MAVS is activated not only by viral RNA sensors such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5), but also by endogenous danger signals. This activation promotes transcription of NLR family pyrin domain-containing 3 (NLRP3) and pro-inflammatory cytokines, and facilitates NLRP3 inflammasome assembly and cytokine maturation, processes implicated in myocardial inflammation, remodelling, and dysfunction in conditions such as myocardial hypertrophy, atherosclerosis, and cardiomyopathy. Beyond inflammasome activation, MAVS intersects with multiple cell death and homeostatic pathways relevant to CVD, including apoptosis, autophagy, and, potentially, ferroptosis. Preclinical studies show that genetic ablation of MAVS, or pharmacological interventions that limit mitochondrial reactive oxygen species (mtROS), mitochondrial double-stranded RNA (mtdsRNA) release, or downstream innate immune signalling, can attenuate MAVS-associated inflammation, oxidative stress, and metabolic remodelling, thereby slowing disease progression in experimental cardiovascular models. MAVS, however, also performs essential protective functions, particularly in antiviral defence and maintenance of cardiac homeostasis, underscoring the need for context-specific, cell-type-restricted, or pathway-selective modulation rather than indiscriminate inhibition. Collectively, these findings position MAVS as a promising therapeutic target in CVD, warranting further investigation into MAVS-associated signalling pathways and their modulation in cardiovascular contexts.
Indexed as
Identifiers
43003868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.